Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 59.9 kDa. The protein migrates as 70-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Mouse Flt-3, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Immobilized Mouse Flt-3, His Tag (Cat. No. FL3-M52H6) at 5 μg/mL (100 μL/well) can bind CD135 (FLT3) Antibody, Anti-mouse with a linear range of 0.02-0.625 μg/mL (Routinely tested).
Mouse Flt-3, His Tag (Cat. No. FL3-M52H6) immobilized on CM5 Chip can bind Mouse Flt-3 Ligand, His Tag (Cat. No. FLL-M52H4) with an affinity constant of 59.6 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Gilteritinib Fumarate | ASP-2215; 66D-92MGC8M (UNII code); ASP-2215 hemifumarate | Approved | Astellas Pharma Inc | Xospata | Mainland China | Leukemia, Myeloid, Acute | Astellas Pharmaceutical (China) Co Ltd | 2018-09-21 | Solid tumours; Renal Insufficiency; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
Midostaurin | PKC-412; PKC-412A; CGP-41231; CGP-41251 | Approved | Novartis Pharma Ag | Rydapt | EU | Leukemia, Myeloid, Acute; Mastocytosis | Novartis Europharm Ltd | 2017-04-28 | Hematologic Neoplasms; Leukemia; Mastocytosis, Systemic; Myelodysplastic Syndromes; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis | Details |
Ponatinib Hydrochloride | AP24534 hydrochloride; AP24534-HCL; AP24534 HCl; INCB-84344; AP-24534 | Approved | Ariad | Iclusig | Japan | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Otsuka Holdings Co Ltd | 2012-12-14 | Blast Crisis; Carcinoma, Non-Small-Cell Lung; Leukemia, Biphenotypic, Acute; Thyroid Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic-Phase; Gastrointestinal Stromal Tumors; Philadelphia Chromosome; Medullary thyroid cancer (MTC); Common Bile Duct Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Glioblastoma; Leukemia, Myelomonocytic, Chronic; Neoplasms; Small Cell Lung Carcinoma; Adenocarcinoma of Lung; Head and Neck Neoplasms; Solid tumours; Leukemia, Myeloid, Accelerated Phase; Leukemia; Hematologic Neoplasms | Details |
Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | EU | systemic sclerosis-associated interstitial lung disease | Boehringer Ingelheim International Gmbh | 2014-10-15 | Gliosarcoma; Breast Neoplasms; Sarcoma; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Genital Neoplasms, Female; Silicosis; Prostatic Neoplasms; Carcinoma, Squamous Cell; Appendiceal Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Colonic Neoplasms; Ovarian Neoplasms; Telangiectasia, Hereditary Hemorrhagic; Esophageal Neoplasms; Rejection of lung transplantation; Carcinoid Tumor; Endometrial Stromal Tumors; Carcinoma, Renal Cell; Radiation Pneumonitis; Neoplasms; Idiopathic Pulmonary Fibrosis; Solid tumours; Scleroderma, Systemic; Glioblastoma; Small Cell Lung Carcinoma; Mesothelioma; Neuroendocrine Tumors; Pulmonary Fibrosis; Lung Diseases, Interstitial; Multiple Myeloma; Asbestosis; Oligodendroglioma | Details |
Pexidartinib | PLX-3397 | Approved | Daiichi Sankyo Co Ltd | Turalio | United States | Giant Cell Tumor of Tendon Sheath | Daiichi Sankyo Inc | 2019-08-02 | Prostatic Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Giant Cell Tumors; Neurofibroma, Plexiform; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neurofibrosarcoma; Sarcoma; Ovarian Neoplasms; Breast Neoplasms; Arthritis, Rheumatoid; Pancreatic Neoplasms; Glioblastoma; Neoplasms; Hodgkin Disease; Synovitis, Pigmented Villonodular; Squamous Cell Carcinoma of Head and Neck; Leukemia, Promyelocytic, Acute; Giant Cell Tumor of Tendon Sheath; Solid tumours | Details |
Quizartinib | AC-220; ASP-2689; AC-010220 | Approved | Ambit Biosciences Co | Vanflyta | Japan | Leukemia, Myeloid, Acute | Daiichi Sankyo Co Ltd | 2019-06-18 | Solid tumours; Leukemia; Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia, Myelomonocytic, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute | Details |
Fedratinib | TG-101348; SAR-302503 | Approved | Sanofi | Inrebic | EU | Primary Myelofibrosis; Splenomegaly | Bristol Myers Squibb Srlcompany | 2019-08-16 | Hematologic Neoplasms; Solid tumours; Polycythemia Vera; Kidney Diseases; Myeloproliferative Disorders; Neoplasms; Leukemia, Neutrophilic, Chronic; Primary Myelofibrosis; Hepatic Insufficiency; Splenomegaly; Thrombocythemia, Essential | Details |
Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | Nexavar, 多吉美 | EU | Thyroid Neoplasms | Bayer AG | 2005-12-01 | Liver Neoplasms; Leukemia, Myeloid; Lymphoma, B-Cell, Marginal Zone; Rhabdomyosarcoma; Head and Neck Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Fibromatosis, Aggressive; Leiomyosarcoma; Kidney Neoplasms; Leukemia, Erythroblastic, Acute; Solid tumours; Lymphoma, T-Cell, Peripheral; Ovarian Neoplasms; Recurrence; Carcinoma, Renal Cell; Esophageal Neoplasms; Vipoma; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Histiocytoma, Malignant Fibrous; Carcinoma, Islet Cell; Hemangiosarcoma; Carcinoid Tumor; Carcinoma; Insulinoma; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Multiple Endocrine Neoplasia Type 2a; Hypertension, Portal; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Thyroid Carcinoma, Anaplastic; Myelodysplastic Syndromes; Glioblastoma; Carcinoma, Ovarian Epithelial; Leukemia, Myelomonocytic, Acute; Colonic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Wilms Tumor; Leukemia, Myelomonocytic, Chronic; Lymphoma, Large-Cell, Immunoblastic; S | Details |
Brigatinib | AP-26113 | Approved | Ariad, Takeda Pharmaceutical Co Ltd | Alunbrig | Mainland China | Carcinoma, Non-Small-Cell Lung | Takeda (China) International Trading Co Ltd | 2017-04-28 | Solid tumours; Ependymoma; Carcinoma; Neoplasms; Neurofibromatosis 2; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Granuloma, Plasma Cell; Lung Neoplasms; Brain metastases; Carcinoma, Non-Small-Cell Lung; Sarcoma, Kaposi; Meningioma; Neurilemmoma; Neuroma, Acoustic | Details |
Pacritinib | SB-1518; ONX-0803 | Approved | Syncore Biotechnology Co Ltd, Concert | VONJO | United States | Primary Myelofibrosis | Cti Biopharma Corp | 2022-02-28 | Lymphoproliferative Disorders; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Thrombocythemia, Essential; Leukemia, Myelomonocytic, Juvenile; Lymphoma, T-Cell; Waldenstrom Macroglobulinemia; Thrombocytopenia; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Myeloid, Acute; Hepatic Insufficiency; Colorectal Neoplasms; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Primary Myelofibrosis; Coronavirus Infections; Lymphoma, Mantle-Cell; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Leukemia, Myelomonocytic, Chronic; Hodgkin Disease; Myeloproliferative Disorders; Myelodysplastic Syndromes; Polycythemia Vera; Lymphoma, T-Cell, Peripheral; Leukemia; Lymphoma, B-Cell | Details |
Cabozantinib S-malate | XL-184; BMS-907351 | Approved | Exelixis Inc | Cometriq, Cabometyx | Japan | Carcinoma, Renal Cell | Takeda | 2012-11-29 | Osteosarcoma; Thyroid Neoplasms; Gliosarcoma; Colorectal Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Hepatic Insufficiency; Astrocytoma; Breast Neoplasms; Sarcoma, Ewing; Lymphoma; Carcinoma, Adenosquamous; Adenocarcinoma, Clear Cell; Sarcoma, Clear Cell; Medullary thyroid cancer (MTC); Cholangiocarcinoma; Prostatic Neoplasms; Neurofibroma, Plexiform; Urethral Neoplasms; Carcinoma, Neuroendocrine; Meningioma; Carcinoma, Non-Small-Cell Lung; Paraganglioma; Melanoma; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Adenocarcinoma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Neuroblastoma; Glioma; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lung Neoplasms; Sarcoma, Alveolar Soft Part; Uterine Neoplasms; Fallopian Tube Neoplasms; Carcinoid Tumor; Neurofibromatoses; Seminoma; Carcinoma, Transitional Cell; Glioblastoma; Rejection of liver transplantation; Carcinoma, Merkel Cell; Hepatoblastoma; Pain; Pheochromocytoma; Neoplasms; Carcinoma, Renal Cell; B | Details |
Sunitinib Malate | PHA-290940; SU-010398; SU-11248; PNU-290940AD; PHA-290940AD; GB-102; PNU-290940; SU-011248-L-malate salt | Approved | Pfizer Pharmaceuticals Ltd (China) | 索坦, Sutent | Japan | Pancreatic neuroendocrine tumors (pNET) | Pfizer Inc | 2006-01-26 | Teratoma; Ovarian Neoplasms; Fibromatosis, Aggressive; Solid tumours; Intestinal Neoplasms; Kidney Neoplasms; Liver Neoplasms; Leiomyosarcoma; Fibrosarcoma; HIV Infections; Head and Neck Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Leukemia, Myeloid, Accelerated Phase; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, T-Cell, Peripheral; Ependymoma; Carcinoma, Renal Cell; Histiocytoma, Malignant Fibrous; Carcinoma; Hemangioblastoma; Carcinoma, Islet Cell; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Thoracic Neoplasms; Leukemia, Hairy Cell; Abdominal Neoplasms; Esophageal Neoplasms; Polycythemia Vera; Pelvic Neoplasms; Pheochromocytoma; Glioblastoma; Neurofibromatoses; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Salivary Gland Neoplasms; Small Cell Lung Carcinoma; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Neoplasms; I | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Sorafenib Tosylate/MG-K10 | MG-D-1609 | Phase 2 Clinical | Solid tumours | Details | |
SEL-24 | SEL-24 program; SEL-24; MEN-1703; SEL-24-1; SEL-24-B489 | Selvita | Details | ||
Luxeptinib | CG-806; CG-026806 | Crystalgenomics Inc, Aptose | Details | ||
R-1530 | RG1530; R-1530; RG-1530 | F. Hoffmann-La Roche Ltd | Details | ||
Flonoltinib maleate | Phase 1 Clinical | Chengdu Zenitar Biomedical Technology Co Ltd | Myeloproliferative Disorders | Details | |
LM-061 | LM-061 | Phase 1 Clinical | Shanghai Lixin Pharmaceutical Research and Development Co Ltd | Solid tumours | Details |
FF-10101 | FF-10101; FF-10101-01; FF-10101 succinate | Fujifilm Corp | Details | ||
AT-9283 | AT-9283 | Otsuka Pharmaceutical Co Ltd | Details | ||
FLX-925 | AMG-925; FLX-925 | Amgen Inc | Details | ||
XY0206 | XY-0206 | Phase 1 Clinical | Shijiazhuang Yiling Pharmaceutical Co Ltd, Nanjing University Of Chinese Medicine | Solid tumours; Leukemia, Myeloid, Acute | Details |
HM-43239 | Hanmi Pharmaceutical Co Ltd | Details | |||
Emirodatamab | AMG-427 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
AKN-028 | BVT-II; AKN-028; BVT-63628 | Akinion | Details | ||
AMG-553 | AMG-553 | Amgen Inc | Details | ||
AGS-62P1 | AGS62P1; ASP-1235 | Ambrx Inc | Details | ||
SC-71710 | 4SC-203; SC-71710 | 4sc Ag, Proqinase | Details | ||
SGI-1776 | SG-0407; SGI-1776 | Astex Pharmaceuticals Inc | Details | ||
HYML-122 | HYML-122; CHMFL-FLT3-122 | Phase 2 Clinical | Hefei Academy Of Physical Sciences, Chinese Academy Of Sciences, Hefei Cosource Pharmaceuticals | Leukemia, Myeloid, Acute | Details |
Anti-FLT3 CAR-T Cell Therapy (PersonGen Biomedicine) | TAA05 | Phase 2 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Leukemia, Myeloid, Acute | Details |
QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
MAX-40279 | MAX-40279-001; Max-40279; MAX-40279-01; MAX-4 | Phase 2 Clinical | Guangzhou Maxinovel Pharmaceiticals Co Ltd | Leukemia; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Myelodysplastic Syndromes; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Neoplasm Metastasis | Details |
NMS-03592088 | NMS-P088; NMS-03592088 | Phase 2 Clinical | Nerviano Medical Sciences Srl | Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | Details |
SKI-G-801 | G-801; SKI-G-801; G-749 Hydrochloride | Phase 1 Clinical | Oscotec Inc | Leukemia, Myeloid, Acute | Details |
RIVAL-01 | TBio-6517; TAK-605 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd, Turnstone Biologics Inc | Solid tumours; Carcinoma, Renal Cell; Mesothelioma; Colorectal Neoplasms; Oropharyngeal Neoplasms; Carcinoma, Squamous Cell; Melanoma; Uterine Cervical Neoplasms | Details |
Crenolanib Besylate | CP-868596-26; IND-112201; CP-868596; ARO-002; ARO-002-26 | Phase 3 Clinical | Pfizer Pharmaceuticals Ltd (China) | Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Acute; Glioma | Details |
FN-1501 | FN-1501; LT-171-861 | Phase 2 Clinical | China Pharmaceutical University, Shanghai Fosun Pharmaceutical Development Ltd | Solid tumours; Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Hepatocellular | Details |
MRX-2843 | MRX-2843; UNC-2025; UNC-2371 | Phase 2 Clinical | Meryx Inc, University Of North Carolina At Chapel Hill, University Of Colorado At Denver | Leukemia; Solid tumours; Neoplasms; Pathologic Processes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lung Neoplasms; Neoplastic Processes; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Lestaurtinib | SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd | Leukemia; Leukemia, Myeloid; Bone Marrow Neoplasms; Polycythemia Vera; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Psoriasis; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential | Details |
Mivavotinib | TAK-659; CB-659 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Lymphoma, B-Cell; Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Plasmablastic Lymphoma; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
E-6201 | E-6201 | Phase 1 Clinical | Eisai Co Ltd | Solid tumours; Neoplasms; Leukemia, Myelomonocytic, Chronic; Myeloproliferative Disorders; Psoriasis; Brain metastases; Leukemia, Myeloid, Acute; Melanoma | Details |
CLN-049 | CLN-049 | Phase 1 Clinical | University Of Tubingen, German Cancer Research Center (Dkfz) | Leukemia, Myeloid, Acute | Details |
LNK-01002 | LNK01002 | Phase 1 Clinical | Lynk Pharmaceutical (Hangzhou) Co Ltd | Hematologic Neoplasms; Primary Myelofibrosis; Leukemia, Myeloid, Acute | Details |
KC1036 | KC1036; KC-1036 | Phase 2 Clinical | Beijing Konruns Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Digestive System Neoplasms; Neoplasm Metastasis | Details |
TT-00973 | TT-00973 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours | Details |
ETH-155008 | ETH-155008 | Phase 1 Clinical | Yunnan Shengke Pharmaceutical Co Ltd | Leukemia; Lymphoma, B-Cell; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin | Details |
SKLB-1028 | SKLB-1028 | Phase 3 Clinical | Sichuan University, CSPC Pharmaceutical Group Ltd | Solid tumours; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute | Details |
Fms-like tyrosine kinase 3 ligand (Celldex Therapeutics) | CDX-301 | Phase 2 Clinical | Amgen Inc | Skin Melanoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Myelodysplastic Syndromes; Hodgkin Disease; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
HH-30134 | HH-30134 | Phase 1 Clinical | ShangHai HaiHe Biopharma Co Ltd | Solid tumours; Neoplasms | Details |
Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Solid tumours; Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Lung Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
HEC-73543 | HEC-73543 | Phase 3 Clinical | Hec Pharm Co Ltd | Leukemia, Myeloid, Acute | Details |
Clifutinib Besylate | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details | |
Emavusertib | CA-4948; AU-4948 | Phase 2 Clinical | Aurigene | Hematologic Neoplasms; Anemia; Esophageal Neoplasms; Stomach Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Famitinib Malate | SHR-1020 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Cholangiocarcinoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Urologic Neoplasms; Genital Neoplasms, Female; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Ovarian Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Pancreatic neuroendocrine tumors (pNET); Nasopharyngeal Neoplasms; Idiopathic Pulmonary Fibrosis; Neoplasms; Carcinoma, Renal Cell; Solid tumours; Biliary Tract Neoplasms | Details |
EP-0042 | Phase 2 Clinical | Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details | ||
Flysyn | 4G8-SDIEM | Phase 2 Clinical | Synimmune Gmbh | Leukemia, Myeloid, Acute | Details |
Zotiraciclib | TG-02; SB-1317 | Phase 2 Clinical | Syncore Biotechnology Co Ltd | Glioblastoma; Neoplasms; Brain Neoplasms; Astrocytoma; Gliosarcoma; Glioma; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
This web search service is supported by Google Inc.